Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $71.77 in the prior trading day, Globus Medical Inc (NYSE: GMED) closed at $71.11, down -0.92%. In other words, the price has decreased by -$0.92 from its previous closing price. On the day, 0.71 million shares were traded. GMED stock price reached its highest trading level at $72.135 during the session, while it also had its lowest trading level at $70.97.
Ratios:
Our goal is to gain a better understanding of GMED by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.07. For the most recent quarter (mrq), Quick Ratio is recorded 1.77 and its Current Ratio is at 2.54. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.02.
On December 02, 2024, Morgan Stanley Upgraded its rating to Overweight which previously was Equal-Weight and also upped its target price recommendation from $83 to $100.
Wells Fargo Upgraded its Equal Weight to Overweight on August 07, 2024, whereas the target price for the stock was revised from $60 to $78.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 28 ’25 when RHOADS ANN D sold 7,500 shares for $78.68 per share. The transaction valued at 590,100 led to the insider holds 35,384 shares of the business.
RHOADS ANN D bought 7,500 shares of GMED for $590,000 on Feb 28 ’25. On Jan 10 ’25, another insider, Pfeil Keith W, who serves as the COO, CFO of the company, sold 14,167 shares for $88.29 each. As a result, the insider received 1,250,770 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 9780612096 and an Enterprise Value of 9428248576. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 95.53, and their Forward P/E ratio for the next fiscal year is 18.14. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.52 while its Price-to-Book (P/B) ratio in mrq is 2.34. Its current Enterprise Value per Revenue stands at 3.742 whereas that against EBITDA is 13.565.
Stock Price History:
The Beta on a monthly basis for GMED is 1.33, which has changed by 0.36881614 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $49.33. The 50-Day Moving Average of the stock is -4.02%, while the 200-Day Moving Average is calculated to be -7.70%.
Shares Statistics:
The stock has traded on average 1.28M shares per day over the past 3-months and 836190 shares per day over the last 10 days, according to various share statistics. A total of 114.99M shares are outstanding, with a floating share count of 114.15M. Insiders hold about 17.01% of the company’s shares, while institutions hold 79.77% stake in the company. Shares short for GMED as of 1744675200 were 4240127 with a Short Ratio of 3.31, compared to 1741910400 on 2423670. Therefore, it implies a Short% of Shares Outstanding of 4240127 and a Short% of Float of 4.1199997.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
